RECAP: CAPA Called on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit.   “Today, millions of patients and families are increasingly impacted by high drug prices while some Big Pharma companies continue abusing the U.S. patent system through anti-competitive tactics that hurt American patients.  By allowing the […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Calls on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit Recently, the U.S. Court of Appeals for the Federal Circuit upheld the verdict in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., subjecting Teva to a $234 million judgment that includes […]

Continue Reading

The Coalition Calls on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit WASHINGTON, DC: Recently, the U.S. Court of Appeals for the Federal Circuit upheld the verdict in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., subjecting Teva to a $234 million judgment that includes damages for the period […]

Continue Reading

New Report Highlights How AbbVie’s Patent System Gaming Keeps Prices High for U.S. Patients WASHINGTON D.C. – In case you missed it, Axios reported this week that international sales of Humira, a medicine that treats a number of chronic conditions and is widely prescribed and used by millions of people around the world, are declining due to the […]

Continue Reading

Congress Must Stop Major Drug Companies from Abusing the U.S. Patent System to Delay or Prevent Patients from Accessing More Affordable Generic Alternative Medications and Treatments. WASHINGTON D.C. – In case you missed it, the Senate Judiciary Committee voted unanimously to pass a package of four bills relating to drug pricing, including S. 1435, the Affordable Prescriptions for […]

Continue Reading